The news is directly related to Replimune Group and is likely to influence investor sentiment. The lowering of the price target might be seen as a slight negative, but the maintenance of the 'Buy' rating indicates continued confidence in the stock. The impact on the stock price in the short term is uncertain, hence the neutral score.